Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | MAOB | P27338 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29929290 | 0.90 | MAOB (0.72) | ALDH1A1CYP3A4MAOBGAAPOLB | |
| SCHEMBL707810 | 0.90 | MAOB (0.72) | ALDH1A1CYP3A4MAOBGAAPOLB | |
| SCHEMBL1271585 | 0.88 | MAOB (0.69) | ALDH1A1CYP3A4MAOBGAAPOLB | |
| SCHEMBL6293108 | 0.88 | MAOB (0.69) | ALDH1A1CYP3A4MAOBGAAPOLB | |
| SCHEMBL6293193 | 0.88 | MAOB (0.69) | ALDH1A1CYP3A4MAOBGAAPOLB | |
| SCHEMBL1271055 | 0.88 | MAOB (0.69) | ALDH1A1CYP3A4MAOBGAAPOLB | |
| SCHEMBL6290515 | 0.88 | MAOB (0.69) | ALDH1A1CYP3A4MAOBGAAPOLB | |
| SCHEMBL6290448 | 0.88 | MAOB (0.69) | ALDH1A1CYP3A4MAOBGAAPOLB | |
| SCHEMBL6290583 | 0.86 | MAOB (0.67) | ALDH1A1CYP3A4MAOBGAAPOLB | |
| SCHEMBL6289928 | 0.86 | MAOB (0.73) | ALDH1A1CYP3A4MAOBGAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586617-B2 | Aminomethyl-4-imidazoles | HOFFMANN-LA ROCHE INC. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2076497-B1 | AMINOMETHYL-4-IMIDAZOLES | HOFFMANN LA ROCHE (CH) | 2012-02-22 | — | — | EP | disclosed |
| EP-2076497-A1 | AMINOMETHYL-4-IMIDAZOLES | F. Hoffmann-Roche AG (CH) | 2009-07-08 | — | — | EP | disclosed |
| US-7402583-B2 | Substituted quinolines as antitumor agents | ASTRZENCA AB (SE) | 2008-07-22 | — | — | US | disclosed |
| US-7402583-B2 | Substituted quinolines as antitumor agents | ASTRZENCA AB (SE) | 2008-07-22 | — | — | US | disclosed |
| US-7402583-B2 | Substituted quinolines as antitumor agents | ASTRZENCA AB (SE) | 2008-07-22 | — | — | US | disclosed |
| US-20080119535-A1 | AMINOMETHYL-4-IMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-22 | — | — | US | disclosed |
| WO-2008046757-A1 | AMINOMETHYL-4-IMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-24 | — | — | WO | disclosed |
| US-20070287716-A1 | Pyrimidine and Quinoline Potentiators of Metabotropic Glutamate Receptors | MERCK SHARP & DOHME CORP. | 2007-12-13 | — | — | US | disclosed |
| EP-1809608-A1 | PYRIMIDINE AND QUINOLINE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Merck & Co., Inc. (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20070021407-A1 | Substituted quinolines as antitumor agents | ASTRAZENECA | 2007-01-25 | — | — | US | disclosed |
| US-20070021407-A1 | Substituted quinolines as antitumor agents | ASTRAZENECA | 2007-01-25 | — | — | US | disclosed |
| US-7067532-B2 | Substituted quinolines as antitumor agents | ASTRAZENECA (SE) | 2006-06-27 | — | — | US | disclosed |
| WO-2006049968-A1 | PYRIMIDINE AND QUINOLINE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK & CO., INC. (US) | 2006-05-11 | — | — | WO | disclosed |
| US-6800651-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2004-10-05 | — | — | US | disclosed |
| US-20040029898-A1 | Substituted quinolines as antitumor agents | ASTRAZENECA AB (SE) | 2004-02-12 | — | — | US | disclosed |
| US-20040006114-A1 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2004-01-08 | — | — | US | disclosed |
| EP-1337524-A1 | SUBSTITUTED QUINOLINES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2003-08-27 | — | — | EP | disclosed |
| WO-2002044166-A1 | SUBSTITUTED QUINOLINES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2002-06-06 | — | — | WO | disclosed |
| US-4783472-A | 1H,3H-pyrrol[1,2-c]thiazole derivatives and pharmaceutical compositions containing them | RHONE-POULENC SANTE (FR) | 1988-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287716-A1 | Pyrimidine and Quinoline Potentiators of Metabotropic Glutamate Receptors | GRM2, GRM1, GRIN2A | ALDH1A1 3466/4885CYP3A4 3745/4885MAOB 2141/4885 |
| US-20070021407-A1 | Substituted quinolines as antitumor agents | NR1H3, NR1H2, NR0B1 | ALDH1A1 3767/4885CYP3A4 576/4885MAOB 3483/4885 |
| US-20040029898-A1 | Substituted quinolines as antitumor agents | NQO2, NQO1, TP53 | ALDH1A1 266/4885CYP3A4 134/4885MAOB 1462/4885 |
| US-20080119535-A1 | AMINOMETHYL-4-IMIDAZOLES | INMT, HTR4, MC4R | ALDH1A1 631/4885CYP3A4 22/4885MAOB 124/4885 |
| US-20040006114-A1 | Potentiators of glutamate receptors | GRM1, GRIN1, GRM2 | ALDH1A1 1187/4885CYP3A4 2786/4885MAOB 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.